GlassScriptPhysician profile
Rabeea Aboufakher
NPI 1881896223
$13,719.03
in general payments reported to CMS, 2019-2025
11 companies · $4,197 in 2025
The $4,197 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,001 · 2020: $89.31 · 2021: $46.02 · 2022: $42.69 · 2023: $160 · 2024: $184 · 2025: $4,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,132 · Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,132.39 |
| Food and Beverage | $1,408.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $6,658.53 | 2019 | |
| Edwards Lifesciences Corporation | $2,642.93 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $1,817.95 | 2019-2023 | Avvigo Guidance System, Filterwire Ez, Comet |
| Medtronic, INC. | $1,658.28 | 2024-2025 | Corevalve Evolut R, Symplicity G3 |
| Siemens Medical Solutions USA, INC. | $829.79 | 2019 | |
| Angiodynamics, INC. | $59.71 | 2025 | Alphavac |
| Cardiva Medical, INC. | $19.89 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Abbott Laboratories | $17.46 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.49 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabeea Aboufakher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.